OTC Markets OTCPK - Delayed Quote USD

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP)

935.22

+3.67

+(0.39%)

As of January 13 at 1:02:47 PM EST. Market Open.

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

-- Bristol Myers Squibb exercises an exclusive license option for ArsenalBio’s AB-4000 series programs -- -- ArsenalBio is eligible for additional milestone payments and royalties as the programs advance -- SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T cell therapies for solid tumors, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised i

GlobeNewswire yesterday

BMY

CELG-RT
AI, vaccine distrust, & the future of healthcare: Novartis CEO

Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline in areas like heart disease and cancer. Still, Narasimhan is feeling pressure to bring the investments to the bottom line to jumpstart its stock price.  In the last year, Novartis shares have declined 6.69%. During that same timespan, the S&P 500 and Dow Jones Industrial Average have gained 22.8% and 12%, respectively. The iShares U.S. Healthcare ETF (IYH) is up slightly in the past year. The stock prices of Pfizer (PFE) and Moderna (MRNA) are down 8.5% and 61%, respectively in the past year. For full episodes of Opening Bid, listen on your favorite podcast platform or watch on our website.

Yahoo Finance Video 4 days ago

PFE

NVS

NVSEF
Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Simply Wall St. 7 days ago

BMY

CELG-RT
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

PRINCETON, N.J., January 03, 2025--Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference

Business Wire 11 days ago

BMY

CELG-RT
Bristol-Myers Squibb's (NYSE:BMY) investors will be pleased with their 2.4% return over the last five years

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Simply Wall St. 12 days ago

BMY

CELG-RT
Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year

Bristol-Myers Squibb Company ( NYSE:BMY ) has announced that it will be increasing its dividend from last year's...

Simply Wall St. 16 days ago

BMY

CELG-RT
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2

PRINCETON, N.J., December 27, 2024--US FDA Approves Opdivo Qvantig Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo Indications

Business Wire 17 days ago

BMY

CELG-RT
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis

PRINCETON, N.J., December 23, 2024--BMS Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis

Business Wire 22 days ago

BMY

CELG-RT
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

PRINCETON, N.J., December 23, 2024--Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult...

Business Wire 22 days ago

BMY

CELG-RT
Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst institutional investors who own 78%

Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive to...

Simply Wall St. 23 days ago

BMY

CELG-RT
Bristol Myers Squibb Stock Earns 83 RS Rating

On Thursday, Bristol Myers Squibb stock got a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83. IBD's proprietary rating tracks price performance with a 1 (worst) to 99 (best) score.

Investor's Business Daily 25 days ago

BMY

CELG-RT

PAHC
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025

PRINCETON, N.J., December 19, 2024--Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025

Business Wire 26 days ago

BMY

CELG-RT
Bristol Myers upgraded to Buy at Jefferies on new launch momentum, pipeline

As previously reported, Jefferies upgraded Bristol Myers (BMY) to Buy from Hold with a price target of $70, up from $63. The firm thinks Cobenfy can become a $10B-plus drug, is getting “increasingly more confident” that Milvexian could hit on non-inferiority and has gotten more visibility on profit-and-loss and thinks the thesis that the EPS floor will break $6 is “gone,” noting that it sees an EPS trough in 2029 or earlier with operating leverage. Published first on TheFly – the ultimate source

TipRanks 28 days ago

BMY

CELG-RT
Bristol-Myers Squibb (NYSE:BMY) Will Pay A Larger Dividend Than Last Year At $0.62

Bristol-Myers Squibb Company ( NYSE:BMY ) has announced that it will be increasing its periodic dividend on the 3rd of...

Simply Wall St. 30 days ago

BMY

CELG-RT
Bristol Myers Squibb Announces Dividend Increase

PRINCETON, N.J., December 11, 2024--Bristol Myers Squibb Announces Dividend Increase

Business Wire last month

BMY

CELG-RT
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline

PRINCETON, N.J., December 09, 2024--Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline

Business Wire last month

BMY

CELG-RT
Dividend Stocks Are Primed for a Comeback in 2025

With highflying tech stocks looking expensive and bonds losing appeal, some investors turn to dividend payers.

The Wall Street Journal last month

SCHW

RJF

PFE
Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference

PRINCETON, N.J., November 26, 2024--Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference

Business Wire last month

BMY

CELG-RT
Bristol-Myers Squibb (NYSE:BMY) increases 4.7% this week, taking one-year gains to 24%

There's no doubt that investing in the stock market is a truly brilliant way to build wealth. But not every stock you...

Simply Wall St. last month

BMY

CELG-RT
AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback

AbbVie stock popped Friday after an analyst upgraded it on the remaining opportunity for its Cerevel takeover despite a huge misstep.

Investor's Business Daily last month

BMY

CELG-RT

ABBV

Performance Overview

Return	BMYMP	S&P 500
YTD	-6.37%	-1.54%
1-Year	+8.39%	+21.58%
3-Year	-27.91%	+24.84%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP)

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

AI, vaccine distrust, & the future of healthcare: Novartis CEO

Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

Bristol-Myers Squibb's (NYSE:BMY) investors will be pleased with their 2.4% return over the last five years

Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2

Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst institutional investors who own 78%

Bristol Myers Squibb Stock Earns 83 RS Rating

Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025

Bristol Myers upgraded to Buy at Jefferies on new launch momentum, pipeline

Bristol-Myers Squibb (NYSE:BMY) Will Pay A Larger Dividend Than Last Year At $0.62

Bristol Myers Squibb Announces Dividend Increase

Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline

Dividend Stocks Are Primed for a Comeback in 2025

Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference

Bristol-Myers Squibb (NYSE:BMY) increases 4.7% this week, taking one-year gains to 24%

AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback

Performance Overview